iToBoS 5th Newsletter launched

The fifth issue of the iToBoS newsletter was released!

Influential policy makers in NTUA European Researchers' Night

During the NTUA European Researchers' Night, co-organized by the National Technical University of Athens (NTUA) and the Technical Chamber of Greece, influential policy makers attended the event.

Spotting the difference: how do you tell melanomas apart from healthy moles?

The earlier you find a skin cancer, the easier and more effective the treatment is. However, it’s not always easy to tell apart harmless, healthy moles and those that need excision and histopathology analysis.

Policymakers and businesspeople visited the iToBoS prototype

During the Bosch Innovation Day held on September 23, 2023, the iToBoS project played a central role at Bosch Madrid.

Anonymization and annotation data flow in the University of Queensland

The data obtained in the University of Queensland (UQ) will follow a specific data flow that will differ slightly on the one followed by the Clínic Hospital in Barcelona.

Assessing UV Damage to the Skin with AI Image Recognition: What You Need to Know

Exposure to sun ultraviolet (UV) radiation can cause significant damage to the skin, leading to premature aging, sunburn, and an increased risk of skin cancer.

Anonymization and annotation data flow in Hospital Clínic Barcelona

In the iToBoS project we will follow two slightly different data flows depending on the point of origin of the patient’s data, due to differences between data protection regulation in Europe vs. Australia.

How to evaluate patient involvement in a research grant application

Soon it will be autumn, the season of changing leaves- and of grant reviews! And with more and more research funders demanding patient involvement, it's also the time for many of us patient advocates to review grants.

The dawn of Artificial Intelligence

Artificial Intelligence (AI) has become an important tool in healthcare in recent years. AI has the ability to analyze large amounts of data and make predictions that can aid doctors in their diagnoses and treatments. This technology has the potential to revolutionize the healthcare industry and improve patient outcomes. 

New partner in iToBoS consortium - Canfield Scientific GMBH

From December 1st, 2022 a new partner officially joined to the iToBoS consortium: Canfield Scientific GMBH. Due the termination of Barco NV’s activities in the project on M18 (September 2022), it was necessary to include a new partner to replace it.